US4411894A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical preparations
Assignee: Hoffmann La Roche Inc
•
Filing: 1981-08-17
•
Granted: 1983-10-25
•
Expires: 2001-08-17
Abstract
Abstract Pharmaceutical compositions useful for the parenteral administration of fat-soluble medicaments are disclosed. The compositions comprise, in addition to the medicaments, a sugar-containing liposome solution or lyophilizates thereof.
Inventors
- 👤 Jurg Schrank
- 👤 Hans Steffen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 15:45
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/10; A61K31/00; A61K31/33; A61K31/395; A61K31/55; A61K31/435; A61K31/47; A61K9/127; A61K9/1277; A61K9/14; A61K9/16
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
50 words
A pharmaceutical composition suitable for parenteral administration of fat-soluble pharmaceutically-active materials which comprises pharmaceutical adjuvants, a fat-soluble pharmaceutically-active material selected from the group consisting of a benzodiazepine or quinolinemethanol derivative, a lecithin of vegetable or animal origin and a sugar component selected from the group consisting of monosaccharides and disaccharides.
Claim 2
Dependent Claim
50 words
A pharmaceutical composition suitable for parenteral administration of fat-soluble pharmaceutically-active materials which comprises pharmaceutical adjuvants, a fat-soluble pharmaceutically-active material selected from the group consisting of a benzodiazepine or quinolinemethanol derivative, a lecithin of vegetable or animal origin and a sugar component selected from the group consisting of monosaccharides and disaccharides.
Claim 3
Dependent Claim
79 words
A pharmaceutical composition suitable for parenteral administration of fat soluble pharmaceutically-active materials which comprises pharmaceutical adjuvants, a fat-soluble pharmaceutically-active material selected from the group consisting of diazepam, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; flunitrazepam, 5-(o-fluorophenyl)-1,3-dihyrdo-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one, and mefloquin, erythro-α-2-piperidyl-2,8 bis-(trifluoromethyl)-4-quinolinemethanol, soya lecithin and a sugar component selected from the group consisting of a monosaccharide and disaccharide, wherein the lecithin concentration ranges, in percent by weight per volume, from about 1 percent to about 25 percent and the sugar component concentration is at least 0.4 molar.
Claim 4
Dependent Claim
79 words
A pharmaceutical composition suitable for parenteral administration of fat soluble pharmaceutically-active materials which comprises pharmaceutical adjuvants, a fat-soluble pharmaceutically-active material selected from the group consisting of diazepam, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; flunitrazepam, 5-(o-fluorophenyl)-1,3-dihyrdo-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one, and mefloquin, erythro-α-2-piperidyl-2,8 bis-(trifluoromethyl)-4-quinolinemethanol, soya lecithin and a sugar component selected from the group consisting of a monosaccharide and disaccharide, wherein the lecithin concentration ranges, in percent by weight per volume, from about 1 percent to about 25 percent and the sugar component concentration is at least 0.4 molar.
Claim 5
Dependent Claim
14 words
The pharmaceutical composition of claim 2 wherein the composition is an aqueous lecithin solution.
Claim 6
Dependent Claim
17 words
The pharmaceutical composition of claim 2 wherein the composition is a lyophilizate of an aqueous lecithin solution.
Claim 7
Dependent Claim
18 words
The pharmaceutical composition of claim 2 wherein the lecithin ranges from about 5 percent to about 15 percent.
Claim 8
Dependent Claim
13 words
The pharmaceutical composition of claim 2 wherein the pharmaceutically-active material is a benzodiazepine.
Claim 9
Dependent Claim
11 words
The pharmaceutical composition of claim 6 wherein the benzodiazepine is 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one.
Claim 10
Dependent Claim
14 words
The pharmaceutical composition of claim 2 wherein the pharmaceutically active material is mefloquin erythro-α-2-piperidyl-2,8-bis-(trifluoromethyl)-4-quinolinemethanol.
References Cited (Backward Citations)
FR2081586B2
Cited
FR2298318B1
Cited
US4158707A
Cited
DE2656333A1
Cited
DE2818655A1
Cited
GB2002319B
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-10-24 | 1987-04-25 | 1987-10-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-10-24 | 1991-04-25 | 1991-10-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-10-24 | 1995-04-25 | 1995-10-25 | $7700.00 | Window Closed / Lapsed |